SEC Form 4 · accession 0001214659-19-001723
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alexander Mark Schobel
Officer — Chief Innovation/Tech Officer
Period of report
Feb 28, 2019
Accepted (ET)
Mar 1, 2019 · 5:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001398733
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 28, 2019 | M | 14,572 | $0.00 | A | 1,034,363 | D | |
| Common Stock | Feb 28, 2019 | F | 6,721 | $8.05 | D | 1,027,642 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3 | $0.00 | Feb 28, 2019 | M | 14,572 | D | Feb 28, 2019 | — | Common Stock | 14,572 | 72,860 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock award. The amount retained by the Company was not in excess of the amount of the tax liability.
- F3There are no expiration dates on RSUs.